Nuclear transcription factor NF-kappa B: Role in biology and medicine

Indian Journal of Experimental Biology

Volumn 42, Issue 4, 2004, Pages 341-353

  Aggarwal, Bharat B ^b   Takada, Yasunari ^b   Shishodia, Shishir ^b   Gutierrez, Angelica M ^b   Oommen, Oommen V ^b   Ichikawa, Haruyo ^b   Baba, Yuh ^b   Kumar, Ashok ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Immunity; Inflammation; NF B; Therapy; Tumorigenesis

Indexed keywords

CELLS; DISEASES; DRUG PRODUCTS; PATHOLOGY;

NUCLEAR TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION PATHWAYS;

CARCINOGENS;

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL; BIOLOGY; GENERAL ASPECTS OF DISEASE; HUMAN; PHYSIOLOGY; REVIEW;

ANIMALS; BIOLOGY; DISEASE; HUMANS; NF-KAPPA B;

ANIMALIA;

EID: 1842423816     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Ghosh S, May M J & Kopp E B, NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol, 16 (1998) 225
2. Pahl H L, Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18, (1999) 6853
3. Li Q & Verma I M, NF-kappaB regulation in the immune system. Nat Rev Immunol, 2 (2002) 725
4. Senftleben U & Karin M, The IKK/NF-kappaB pathway. Crit Care Med, 30 (2002) S18
5. Silverman N, Maniatis T, NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev, 15, (2001) 2321
6. Karin M & Delhase M, The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signaling, Semin Immunol, 12 (2000) 85
7. Karin M & Lin A, NF-kappaB at the crossroads of life and death. Nat Immunol, 3 (2002) 221.
8. Kumar A, Lnu S, Malya R, Barron D, Moore J & Corry D B & Boriek A M, Mechanical stretch activates nuclear factor-kappaB, activator protein-1, and mitogen-activated protein kinases in lung parenchyma: Implications in asthma. FASEB J, 17 (2003) 1800.
9. Kumar A & Boriek A M, Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: A possible role in Duchenne muscular dystrophy. FASEB J, 17 (2003) 386.
10. Karin M & Ben-Neriah Y, Regulatory functions of ubiquitination in the immune system. Nat Immunol, 3 (2002) 2.
11. Wilkinson K D, Signal transduction: Aspirin, ubiquitin and cancer. Nature, 424 (2003) 738.
12. Chen Z J, Parent L, Maniatis T, Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell, 84 (1996) 853.
13. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M, The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IK□Beta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell, 91 (1997) 243.
14. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M, A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature, 388 (1997) 548.
15. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ, Israel A, Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell, 93 (1998) 1231.
16. Rothwarf DM, Zandi E, Natoli G, Karin M, IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature, 395 (1998) 297.
17. Ling L, Cao Z, Goeddel DV, NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci U S A, 95 (1998) 3792.
18. Lee FS, Peters RT, Dang LC, Maniatis T, MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc Natl Acad Sci U S A, 95 (1998) 9319.
19. Karin M, The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem, 274 (1999) 27339.
20. Li N, Karin M, Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci U S A, 95 (1998) 13012.
21. Bender K, Gottlicher M, Whiteside S, Rahmsdorf HJ, Herrlich P, Sequential DNA damage-independent and -dependent activation of NF-kappaB by UV. EMBO J, 17 (1998) 5170.
22. Kato Jr T, Delhase M, Hoffmann A, Karin M, CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell, 12 (2003) 829.
23. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, Peyron JF, Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell, 86 (1996) 787.
24. Singh S, Darnay BG, Aggarwal BB, Site-specific tyrosine phosphorylation of Ikappa B alpha negatively regulates its inducible phosphorylation and degradation. J Biol Chem, 271 (1996) 31049.
25. Mukhopadhyay A, Manna SK, Aggarwal BB, Pervanadate-induced nuclear factor-kappaB activation requires tyrosine phosphorylation and degradation of IkappaBalpha. Comparison with tumor necrosis factor-alpha. J Biol Chem, 275 (2000) 8549.
26. Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, Aggarwal BB, Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: Evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem, 278 (2003) 24233.
27. Li N, Karin M, Is NF-kappaB the sensor of oxidative stress? FASEB J, 13 (1999) 1137.
28. Fan C, Li Q, Ross D, Engelhardt J F, Tyrosine phosphorylation of I kappa B alpha activates NF kappa B through a redox-regulated and c-Src-dependent mechanism following hypoxia/reoxygenation. J Biol Chem, 278 (2003) 2072.
29. Bui NT, Livolsi A, Peyron JF, Prehn JH, Activation of nuclear factor kappaB and Bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IkappaBalpha. J Cell Biol, 152 (2001) 753.
30. Digicaylioglu M, Lipton SA, Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature, 412 (2001) 641.
31. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE, Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene, 20 (2001) 1287.
32. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA, Possible new role for NF-kappaB in the resolution of inflammation. Nat Med, 7 (2001) 1291.
33. Karin M, Takahashi T, Kapahi P, Delhase M, Chen Y, Makris C, Rothwarf D, Baud V, Natoli G, Guido F, Li N, Oxidative stress and gene expression: The AP-1 and NF-kappaB connections. Biofactors, 15 (2001) 87.
34. Zhou LZ, Johnson AP, Rando TA, NF kappa B and AP-1 mediate transcriptional responses to oxidative stress in skeletal muscle cells. Free Radic Biol Med, 31 (2001) 1405.
35. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D, Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature, 376 (1995) 167.
36. Doi T S, Takahashi T, Taguchi O, Azuma T & Obata Y, NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med, 185 (1997) 953.
37. Senftleben U, Li Z W, Baud V & Karin M, IK□Beta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity, 14 (2001) 217.
38. Sha W C, Liou H C, uomanen E I & Baltimore D, Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell, 80 (1995) 321.
39. Burkly L, Hession C, Ogata L, Reilly C, Marconi L A, Olson D, Tizard R, Cate R & Lo D, Expression of relB is required for the development of thymic medulla and dendritic cells. Nature, 373 (1995) 531.
40. Weih F, Carrasco D, Durham S K, Barton D S, Rizzo C A, Ryseck R P, Lira S A & Bravo R, Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell, 80 (1995) 331.
41. Kontgen F, Grumont R J, Strasser A, Metcalf D, Li R, Tarlinton D & Gerondakis S, Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev, 9 (1995) 1965.
42. Caamano J H, Rizzo C A, Durham S K, Barton D S, Raventos-Suarez C, Snapper C M & Bravo R, Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med, 187 (1998) 185.
43. Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, Sanjo H, Yoshikawa K, Terada N & Akira S, Limb and skin abnormalities in mice lacking IKK-alpha. Science, 284 (1999) 313.
44. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R & Karin M, Abnormal morphogenesis but intact IKK activation in mice lacking the IKK-alpha subunit of IkappaB kinase. Science, 284 (1999) 316.
45. Senftleben U, Cao Y, Xiao G, Greten F R, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun S C & Karin M, Activation by IKK-alpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 293 (2001) 1495.
46. Li Q, Van Antwerp D, Mercurio F, Lee K F & Verma I M, Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science, 284 (1999) 321.
47. Li Z W, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R & Karin M, The IK□Beta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med, 189 (1999) 1839.
48. Rudolph D, Yeh W C, Wakeham A, Rudolph B, Nallainathan D, Potter J, Elia A J & Mak T W, Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKK-gamma-deficient mice. Genes Dev, 14 (2000) 854.
49. Makris C, Godfrey V L, Krahn-Senftleben G, Takahashi T, Roberts J L, Schwarz T, Feng L, Johnson R S & Karin M, Female mice heterozygous for IKK-gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell, 5 (2000) 969.
50. Guttridge D C, Albanese C, Reuther J Y, Pestell R G & Baldwin A S J, NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol, 19 (1999) 5785.
51. Bharti A C & Aggarwal B B, Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol, 64 (2002) 883.
52. Giri D K & Aggarwal B B, Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem, 273 (1998) 14008.
53. Rath P C &, Aggarwal B B, Antiproliferative effects of IFN-alpha correlate with the downregulation of nuclear factor-kappa B in human Burkitt lymphoma Daudi cells. J Interferon Cytokine Res, 21 (2001) 523.
54. Younes A, Garg A & Aggarwal B B, Nuclear transcription factor-kappaB in Hodgkin's disease. Leuk Lymphoma, 44 (2003) 929.
55. Chen F, Castranova V & Shi X, New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol, 159 (2001) 387.
56. Bharti A C, Donato N, Singh S & Aggarwal B B, Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood, 101 (2003) 1053.
57. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P & Aggarwal B B, Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene, 20 (2001) 7597.
58. Rayet B & Gelinas C, Aberrant rel/nf□B genes and activity in human cancer. Oncogene, 18 (1999) 6938.
59. Yamamoto Y & Gaynor R B, Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest, 107 (2001) 135.
60. van Hogerlinden M, Rozell B L, Ahrlund-Richter L & Toftgard R, Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res, 59 (1999) 3299.
61. Seitz C S, Lin Q, Deng H & Khavari P A, Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA, 95 (1998) 2307.
62. Dajee M, Lazarov M, Zhang J Y, Cai T, Green C L, Russell A J, Marinkovich M P, Tao S, Lin Q, Kubo Y & Khavari P A, NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature, 421 (2003) 639.
63. Hinata K, Gervin A M, Jennifer Zhang Y & Khavari P A, Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene, 22 (2003) 1955.
64. Nabel G & Baltimore D, An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature, 326 (1987) 711.
65. Hiscott J, Kwon H & Genin P, Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest, 107 (2001) 143.
66. Surabhi R M & Gaynor R B, RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol, 76 (2002) 12963.
67. Quinto I, Mallardo M, Baldassarre F, Scala G, Englund G & Jeang K T, Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development. J Biol Chem, 274 (1999) 17567.
68. Kwon H, Pelletier N, DeLuca C, Genin P, Cisternas S, Lin R, Wainberg M A & Hiscott J, Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells. J Biol Chem, 273 (1998) 7431.
69. Christman J W, Sadikot R T & Blackwell T S, The role of nuclear factor-kappa B in pulmonary diseases. Chest, 117 (2000) 1482.
70. Poynter M E, Irvin C G & Janssen-Heininger Y M, Rapid activation of nuclear factor-kappaB in airway epithelium in a murine model of allergic airway inflammation. Am J Pathol, 160 (2002) 1325.
71. Hart L A, Krishnan V L, Adcock I M, Barnes P J & Chung K F, Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med, 158 (1998) 1585.
72. Bureau F, Bonizzi G, Kirschvink N, Delhalle S, Desmecht D, Merville M-P, Bours V & Lekeux P, Correlation between nuclear factor-B activity in bronchial brushing samples and lung dysfunction in an animal model of asthma. J Respir Crit Care Med, 161 (2000) 1314.
73. Bureau F, Delhalle S, Bonizzi G, Fievez L, Dogne S, Kirschvink N, Vanderplasschen A, Merville M P, Bours V & Lekeux P, Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. J Immunol, 165 (2000) 5822.
74. Henderson W R J, Chi E Y, eo J L, Guyen C, Ahn M, A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol, 169 (2002) 5294.
75. Stacey M A, Sun G, Vassalli G, Marini M, Bellini A & Mattoli S, The allergen Der p1 induces NF-kappaB activation through interference with IkappaB alpha function in asthmatic bronchial epithelial cells. Biochem Biophys Res Commun, 236 (1997) 522.
76. Jaspers I, Flescher E & Chen L C, Ozone-induced IL-8 expression and transcription factor binding in respiratory epithelial cells. Am J Physiol, 272 (1997) L504.
77. Nicholson KG, Kent J & Ireland D C, Respiratory viruses and exacerbations of asthma in adults. Br Med J, 307 (1993) 982.
78. Hosoda M, Yamaya M, Suzuki T, Yamada N, Kamanaka M, Sekizawa K, Butterfield J H, Watanabe T, Nishimura H, Sasaki H, Effects of rhinovirus infection on histamine and cytokine production by cell lines from human mast cells and basophils. J Immunol, 169 (2002) 1482.
79. Papi A, Johnston S L, Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription. J Biol Chem, 274 (1999) 9707.
80. Papi A & Johnston S L, Respiratory epithelial cell expression of vascular cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappaB and GATA transcription factors. J Biol Chem, 274 (1999) 30041.
81. Brar S S, Kennedy T P, Sturrock A B, Huecksteadt T P, Quinn M T, Murphy T M, Chitano P & Hoidal J R, NADPH oxidase promotes NF-kappaB activation and proliferation in human airway smooth muscle. Am J Physiol, 282 (2002) L782.
82. Barnes P J, Inhaled glucocorticoids for asthma. N Engl J Med, 332 (1995) 868.
83. Barnes P J, Adcock I M, Transcription factors and asthma. Eur Respir J, 12 (1998) 221.
84. Auphan N, DiDonato J A, Rosette C, Helmberg A & Karin M, Immunosuppression by glucocorticoids: Inhibition of NF-B activity through induction of I-B synthesis. Science, 270 (1995) 286.
85. Hart L, Lim S, Adcock I, Barnes P J & Chung K F, Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma. Am J Respir Crit Care Med, 161 (2000) 224.
86. Hancox R J, Stevens D A, Adcock I M, Barnes P J & Taylor D R, Effects of inhaled beta agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax, 54 (1999) 488.
87. Wong S C, Fukuchi M & Melnyk P, Rodger I, Giaid A, Induction of cyclooxygenase-2 and activation of nuclear factor kappaB in myocardium of patients with congestive heart failure. Circulation, 98 (1998) 100.
88. Devaux B, Scholz D, Hirche A, Klovekorn W P & Schaper J, Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J, 18 (1997) 470.
89. Frantz S, Fraccarollo D, Wagner H, Behr T M, Jung P, Angermann C E, Ertl G & Bauersachs J, Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res, 57 (2003) 749.
90. Valen G, Yan Z Q & Hansson G K, Nuclear factor kappa-B and the heart. J Am Coll Cardiol, 38 (2001) 307.
91. Shimizu N, Yoshiyama M, Omura T, Hanatani A, Kim S, Takeuchi K, Iwao H, Yoshikawa J, Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res, 38 (1998) 116.
92. Chandrasekar B, Freeman G L, Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett, 401 (1997) 30.
93. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T, In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med, 3 (1997) 894.
94. Levy D, Garrison R J, Savage D D, Kannel W B & Castelli W P, Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med, 322 (1990) 1561.
95. Purcell N H & Molkentin J D, Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy? Circulation, 108 (2003) 638.
96. Purcell N H, Tang G, Yu C, Mercurio F, DiDonato J A & Lin A, Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A, 98 (2001) 6668.
97. Gupta S, Purcell N H, Lin A & Sen S, Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol, 159 (2002) 1019.
98. Hirotani S, Otsu K, Nishida K, Higuchi Y, Monta T, Nakayama H, Yamaguchi O, Mano T, Matsumura Y, Ueno H, Tada M & Hori M, Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation, 105 (2002) 509.
99. Cook S A, Novikov M S, Ahn Y, Matsui T & Rosenzweig A, A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation, 108 (2003) 664.
100. Smahi A, Courtois G, Rabia S H, Doffinger R & Israel A, The NF-kappaB signaling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Human Mol Genet, 11 (2002) 2371.
101. Aradhya S & Nelson D L, NF-kappaB signaling and human disease. Curr Opin Genet Dev, 11 (2001) 300.
102. Landy S J & Donnai D, Incontinentia pigmenti (Bloch-Sulzberger syndrome). J Med Genet, 30 (1993) 53.
103. Smahi A & Courtois G et al, Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature, 405 (2000) 466.
104. Wang C Y, Cusack J C Jr, Liu R & Baldwin A S Jr, Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med, 5 (1999) 412.
105. Epinat J C & Gilmore T D, Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene, 18 (1999) 6896.
106. Bondeson J, Foxwell B, Brennan F & Feldmann M, Defining therapeutic targets by using adenovirus: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA, 96 (1999) 5668.
107. Wang C Y, Cusack J C J, Liu R & Baldwin A S J, Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med, 5 (1999) 412.
108. Zingarelli B, Sheehan M 7 Wong H R, Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med, 31 (2003) S105.
109. Kupatt C, Wichels R, Deiss M, Molnar A, Lebherz C, Raake P, von Degenfeld G, Hahnel D & Boekstegers P, Retroinfusion of NF kappa B decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs. Gene Ther, 9 (2002) 518.
110. Yokoseki O, Suzuki J, Kitabayashi H, Watanabe N, Wada Y, Aoki M, Morishita R, Kaneda Y, Ogihara T, Futamatsu H, Kobayashi Y & Isobe M, cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res, 89 (2001) 899.
111. Mann M J & Dzau V J, Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest, 106 (2002) 1071.
112. Yin M J, Yamamoto Y & Gaynor R B, The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature, 396, (1998) 77.
113. Haefner B, NF-kappa B: Arresting a major culprit in cancer. Drug Discov Today, 7 (2002) 653.
114. Adams J, Palombella V J & Elliott P J, Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs, 18 (2000) 109.
115. Mitchell B S, The proteasome - An emerging therapeutic target in cancer. N Engl J Med, 348 (2003) 2597.